Status: Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
Participants needed: 448
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Alterome Therapeutics, Inc.Updated: Jun 10, 2026Locations: 12
Eligibility criteria
Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS... [+4]
Prior treatment with a KRAS inhibitor, certain exceptions are described in the f... [+1]